Search

Displaying results 2511 - 2520 of 3732 in total
  1. Drug

    Temsavir

    go.drugbank.com/drugs/DB14675
    Investigational

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Cortisone

    go.drugbank.com/drugs/DB14681
    Investigational

    A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone...

    Categories: Corticosteroid Hormone Receptor Agonists, Cytochrome P-450 CYP3A Inducers
  3. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, prog...

    Categories: P-glycoprotein substrates
  4. Drug

    Mavacamten

    go.drugbank.com/drugs/DB14921
    ApprovedInvestigational

    Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is ...

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  5. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth

    Categories: Somatostatin Receptor Agonists, P-glycoprotein inhibitors
  6. Drug

    Vicagrel

    go.drugbank.com/drugs/DB16349
    Investigational

    Vicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  7. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR).

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  8. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

  9. Drug

    Goldenseal

    go.drugbank.com/drugs/DB16594
    Approved

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors
  10. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the ROS1 gene. ROS1 mutations are one...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates